PL2158319T3 - Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie - Google Patents

Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie

Info

Publication number
PL2158319T3
PL2158319T3 PL08757088T PL08757088T PL2158319T3 PL 2158319 T3 PL2158319 T3 PL 2158319T3 PL 08757088 T PL08757088 T PL 08757088T PL 08757088 T PL08757088 T PL 08757088T PL 2158319 T3 PL2158319 T3 PL 2158319T3
Authority
PL
Poland
Prior art keywords
amino acid
alkaline phosphatase
kits
methods
bone targeted
Prior art date
Application number
PL08757088T
Other languages
English (en)
Other versions
PL2158319T4 (pl
Inventor
Philippe Crine
Guy Boileau
Thomas P Loisel
Isabelle Lemire
Pierre Leonard
Robert Heft
Hal Landy
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of PL2158319T3 publication Critical patent/PL2158319T3/pl
Publication of PL2158319T4 publication Critical patent/PL2158319T4/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Adornments (AREA)
  • Cereal-Derived Products (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL08757088T 2007-05-11 2008-05-12 Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie PL2158319T4 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
EP08757088A EP2158319B1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof
PCT/CA2008/000923 WO2008138131A1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Publications (2)

Publication Number Publication Date
PL2158319T3 true PL2158319T3 (pl) 2012-05-31
PL2158319T4 PL2158319T4 (pl) 2016-04-29

Family

ID=40001639

Family Applications (3)

Application Number Title Priority Date Filing Date
PL13002327T PL2662448T3 (pl) 2007-05-11 2008-05-12 Kierowana do kości fosfataza alkaliczna, zestawy i sposoby jej zastosowania
PL11004496T PL2368999T3 (pl) 2007-05-11 2008-05-12 Kierowana do kości fosfataza alkaliczna, zestawy oraz metody wykorzystywania
PL08757088T PL2158319T4 (pl) 2007-05-11 2008-05-12 Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL13002327T PL2662448T3 (pl) 2007-05-11 2008-05-12 Kierowana do kości fosfataza alkaliczna, zestawy i sposoby jej zastosowania
PL11004496T PL2368999T3 (pl) 2007-05-11 2008-05-12 Kierowana do kości fosfataza alkaliczna, zestawy oraz metody wykorzystywania

Country Status (25)

Country Link
US (1) US20100297119A1 (pl)
EP (3) EP2158319B1 (pl)
JP (1) JP5732603B2 (pl)
AT (1) ATE536413T1 (pl)
AU (1) AU2008250945B2 (pl)
BR (2) BR122019000505B1 (pl)
CA (1) CA2687001C (pl)
CY (1) CY2016005I1 (pl)
DE (1) DE202008018131U1 (pl)
DK (3) DK2158319T3 (pl)
ES (3) ES2471915T3 (pl)
FR (1) FR16C0007I2 (pl)
HR (1) HRP20140416T1 (pl)
HU (2) HUE031655T2 (pl)
IL (1) IL202057A0 (pl)
LT (1) LTC2368999I2 (pl)
LU (1) LU92976I2 (pl)
ME (1) ME01828B (pl)
NL (1) NL300798I2 (pl)
NO (1) NO2016002I1 (pl)
PL (3) PL2662448T3 (pl)
PT (3) PT2662448T (pl)
RS (1) RS53302B (pl)
SI (2) SI2368999T1 (pl)
WO (1) WO2008138131A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
CN101835802B (zh) 2007-06-01 2014-04-09 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
BR112012027765A2 (pt) 2010-04-30 2019-09-24 Enobia Pharma Inc. métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
WO2012016073A2 (en) 2010-07-28 2012-02-02 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
US9926544B2 (en) * 2014-01-24 2018-03-27 Am-Pharma B.V. Chimeric alkaline phosphatase-like proteins
US10822596B2 (en) * 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
LT3325011T (lt) 2015-07-24 2021-01-25 Gliknik Inc. Iš žmogaus baltymo fragmentų sulieti baltymai, siekiant sukurti tvarkingai multimerizuoto imunoglobulino fc kompozicijas su padidintu komplemento surišimu
JP6993961B2 (ja) * 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (en) * 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) * 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20240160671A (ko) 2016-04-01 2024-11-11 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
EP3464573B1 (en) 2016-06-06 2026-03-04 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
WO2018004517A1 (en) 2016-06-27 2018-01-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
WO2018102616A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
CN110177802A (zh) 2016-12-09 2019-08-27 格利克尼克股份有限公司 多聚化stradomer GL-2045的制造优化
CA3043251A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
WO2018164995A1 (en) * 2017-03-09 2018-09-13 Alexion Pharmaceuticals, Inc . Glycoprotein manufacturing process
KR20190129058A (ko) * 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
CA3087569A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
ES2972119T3 (es) 2018-08-10 2024-06-11 Alexion Pharma Inc Cicatrización ósea en implantes utilizando fosfatasa alcalina
KR20220005560A (ko) 2019-05-06 2022-01-13 신세틱 바이오로직스, 인코퍼레이티드 알칼리성 포스페이트-기반 종양학 치료제
KR20220111693A (ko) * 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법
EP4084819A1 (en) 2020-01-03 2022-11-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Tnap locally administered for promoting periodontal health
AU2021338361A1 (en) * 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
US12083169B2 (en) * 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US20260027233A1 (en) * 2022-08-31 2026-01-29 University Of Utah Research Foundation Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ES2284545T3 (es) 1999-11-16 2007-11-16 Genzyme Corporation Vectores y transgenes con elementos reguladores para la administracion de genes del higado.
ATE437221T1 (de) 2001-05-14 2009-08-15 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
EP1781318A4 (en) 2004-06-23 2009-12-23 Genzyme Corp METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYKYSTIC DISEASES
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
CN101068575A (zh) 2004-12-01 2007-11-07 建新公司 向肝脏定向递送遗传物质的方法

Also Published As

Publication number Publication date
LU92976I2 (en) 2016-04-11
FR16C0007I2 (fr) 2017-01-27
DK2662448T3 (en) 2017-03-20
ES2380546T3 (es) 2012-05-16
BRPI0811198A2 (pt) 2014-10-21
AU2008250945A2 (en) 2009-12-24
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
FR16C0007I1 (pl) 2016-04-15
LTPA2016004I1 (lt) 2016-02-25
DK2368999T3 (da) 2014-05-26
CY2016005I2 (el) 2016-08-31
EP2158319A1 (en) 2010-03-03
EP2158319A4 (en) 2010-07-21
NL300798I1 (pl) 2016-03-16
AU2008250945B2 (en) 2013-12-12
JP5732603B2 (ja) 2015-06-10
BR122019000505A2 (pt) 2021-12-14
EP2368999A1 (en) 2011-09-28
PL2368999T3 (pl) 2014-08-29
HRP20140416T1 (hr) 2014-06-20
WO2008138131A9 (en) 2009-08-06
PT2662448T (pt) 2017-03-29
NO2016002I2 (no) 2016-02-02
CY2016005I1 (el) 2016-08-31
PL2662448T3 (pl) 2017-07-31
HK1141047A1 (en) 2010-10-29
ME01828B (me) 2014-12-20
SI2662448T1 (sl) 2017-05-31
BR122019000505B1 (pt) 2022-01-18
JP2010526543A (ja) 2010-08-05
PL2158319T4 (pl) 2016-04-29
NL300798I2 (pl) 2016-03-16
LTC2368999I2 (lt) 2017-09-25
DE202008018131U1 (de) 2011-12-30
HK1191372A1 (en) 2014-07-25
DK2158319T3 (da) 2012-03-19
PT2158319E (pt) 2012-03-06
AU2008250945A1 (en) 2008-11-20
NO2016002I1 (no) 2016-02-02
CA2687001C (en) 2019-02-12
EP2158319B1 (en) 2011-12-07
HUS1600005I1 (hu) 2016-02-29
RS53302B (sr) 2014-08-29
SI2368999T1 (sl) 2014-07-31
IL202057A0 (en) 2011-08-01
BRPI0811198B8 (pt) 2021-05-25
ES2619332T3 (es) 2017-06-26
ATE536413T1 (de) 2011-12-15
US20100297119A1 (en) 2010-11-25
BRPI0811198A8 (pt) 2018-08-14
BRPI0811198B1 (pt) 2021-03-09
HK1162589A1 (en) 2012-08-31
WO2008138131A1 (en) 2008-11-20
PT2368999E (pt) 2014-05-26
ES2471915T3 (es) 2014-06-27
EP2662448B1 (en) 2016-12-21
EP2368999B1 (en) 2014-03-12
WO2008138131A4 (en) 2008-12-31
CA2687001A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
NL300798I2 (pl)
HUS2000011I1 (hu) A 2,4-pirimidin-diamin vegyületek elõgyógyszerei és alkalmazásuk
BRPI0414593A (pt) derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1
ATE481987T1 (de) Verfahren zur radiofluoridierung von biologisch aktiven vektoren
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
BRPI0414598A (pt) indóis substituìdos
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
HRP20090245T1 (en) Pyy agonists and uses thereof
IL186741A0 (en) Optical probe for delivery of light
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
MX347545B (es) Polipeptidos con actividad xilanasa.
DE602004025576D1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
HUP0101317A2 (hu) Módosított VIII-as faktor
HRP20090074T3 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
CR10303A (es) "derivados de quinolina y su uso com pesticidas"
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
BRPI0406704A (pt) Antagonistas de 5ht~7~ e agonistas inversos
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
SE0302103D0 (sv) Xylanases with enhanced thermophilicity and alkalophilicity
DK2084198T3 (da) Beklædningssammensætning
EP2004352A4 (en) AMINO ACID SUPPLEMENT FOR PEPTIDE CONSTRUCTIONS
MY150639A (en) T cell adhesion molecule and antibody thereto
MXPA05013239A (es) Compuestos de amida y metodos para controlar enfermedades vegetales con los mismos.